Lumos Diagnostics’ FebriDx point-of-care test will have to wait a bit longer to see the light of day in the U.S., as the Australian company announced (PDF) Monday that its 510(k) submission to the FDA ...
Lumos teams up with AcuityMD to strengthen US commercialisation of its rapid FebriDx test to distinguish between bacterial and non-bacterial acute respiratory infections. The collaboration will ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback